Investigational Drug Shows Early Promise in NRAS-Mutant Melanoma
University of Utah Health reports an investigational drug shows promise in NRAS-driven melanoma, a subtype lacking targeted options beyond checkpoint immunotherapy.
Topic
Nras Mutant
Topic